Octreotide Completed Phase 4 Trials for Neoplastic Disease Treatment

Back to Octreotide
IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT01789281Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.